Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

R Franca, P Rebora, N Bertorello, F Fagioli, V Conter, A Biondi, A Colombini, C Micalizzi, M Zecca, R Parasole, F Petruzziello, G Basso, M C Putti, Locatelli, P d'Adamo, M G Valsecchi, G Decorti, M Rabusin

Research output: Contribution to journalArticlepeer-review


Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4%); HEP in 204 (40.2%) and NEU in 44 (8.7%). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalPharmacogenomics Journal
Issue number1
Publication statusPublished - Jan 2017


  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols
  • Chemical and Drug Induced Liver Injury
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Consolidation Chemotherapy
  • Female
  • Gastrointestinal Diseases
  • Gene Deletion
  • Genetic Predisposition to Disease
  • Glutathione Transferase
  • Humans
  • Induction Chemotherapy
  • Infant
  • Logistic Models
  • Male
  • Multidrug Resistance-Associated Proteins
  • Multiplex Polymerase Chain Reaction
  • Mutation
  • Nervous System Diseases
  • Pharmacogenetics
  • Pharmacogenomic Testing
  • Pharmacogenomic Variants
  • Phenotype
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Predictive Value of Tests
  • Pyrophosphatases
  • Receptor, Adenosine A2A
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Journal Article


Dive into the research topics of 'Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol'. Together they form a unique fingerprint.

Cite this